Last €0.14 EUR
Change Today +0.012 / 9.45%
Volume 2.5K
LAVI On Other Exchanges
Symbol
Exchange
Athens
Berlin
As of 10:10 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

lavipharm s.a. (LAVI) Snapshot

Open
€0.14
Previous Close
€0.13
Day High
€0.14
Day Low
€0.14
52 Week High
11/8/13 - €0.19
52 Week Low
06/26/13 - €0.10
Market Cap
7.1M
Average Volume 10 Days
6.3K
EPS TTM
€-0.26
Shares Outstanding
51.1M
EX-Date
06/5/09
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LAVIPHARM S.A. (LAVI)

Related News

No related news articles were found.

lavipharm s.a. (LAVI) Related Businessweek News

No Related Businessweek News Found

lavipharm s.a. (LAVI) Details

Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company offers a range of pharmaceutical products in the areas of cardiology, chronic pain, oncology, central nervous system, dermatological treatment, general medicine, respiratory system, and urology. It also provides over the counter (OTC) products, including antiseptics, analgesics, and natural products, as well as gastrointestinal, gynecological, dermatological, and anti-lice treatment products; and dermocosmetics, such as skincare products. In addition, the company offers Trinipatch, a nitroglycerine transdermal delivery system used for the prevention of angina. Its product pipeline includes nicotine transdermal system for smoking cessation; various OTC products for the symptoms of common cold, oral hygiene, and excessive excretion of shawl; and food supplements based on cereal and fruit oils for skin and hair health. It primarily serves health professionals, physicians, and pharmacists. Lavipharm S.A. was founded in 1911 and is headquartered in Paiania, Greece.

Founded in 1911

lavipharm s.a. (LAVI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lavipharm s.a. (LAVI) Key Developments

Lavipharm S.A. Announces Earnings Results for the Year Ended December 31, 2011

Lavipharm S.A. announced earnings results for the year ended December 31, 2011. For the year, the company reported total revenue of EUR 168.7 million against EUR 168.43 million a year ago. Operating loss was EUR 3.99 million against operating income of EUR 6.14 million a year ago. Pre-tax loss was EUR 13.44 million against pre-tax income of EUR 0.88 million a year ago. Total net loss was EUR 10.39 million against EUR 3.75 million a year ago. Cash from operating activities was EUR 14.88 million against EUR 1.13 million a year ago. Capital expenditures was EUR 0.82 million against EUR 0.47 million a year ago. Negative return on equity was 59.44% against 13% a year ago. Negative return on assets was 7.13% against 1.95% a year ago.

Lavipharm S.A. Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2012

Lavipharm S.A. reported consolidated and parent earnings results for the second quarter and six months ended June 30, 2012. For the quarter, on the consolidated basis, the company's operating revenues were EUR 8,984,000 compared to EUR 46,131,000 a year ago. LBIT was EUR 119,000 compared to EBIT of EUR 818,000 a year ago. Loss before taxes was EUR 2,119,000 compared to EUR 1,583,000 a year ago. Loss after taxes distributed to shareholders was EUR 2,041,000 compared to EUR 1,226,000 a year ago. Total loss after taxes distributed to shareholders was EUR 3,156,000 compared to EUR 1,164,000 a year ago. Basic loss per share was EUR 0.0400 compared to EUR 0.0240 a year ago. EBITDA was EUR 757,000 compared to EUR 1,794,000 a year ago. For the six months, on the consolidated basis, the company's operating revenues were EUR 18,989,000 compared to EUR 94,163,000 a year ago. LBIT was EUR 1,161,000 compared to EBIT of EUR 332,000 a year ago. Loss before taxes was EUR 5,435,000 compared to EUR 4,661,000 a year ago. Loss after taxes distributed to shareholders was EUR 4,685,000 compared to EUR 3,543,000 a year ago. Total loss after taxes distributed to shareholders was EUR 5,225,000 compared to EUR 2,677,000 a year ago. Basic loss per share was EUR 0.0917 compared to EUR 0.0694 a year ago. EBITDA was EUR 593,000 compared to EUR 2,183,000 a year ago. Net cash flows from operating activities were EUR 16,087,000 compared to EUR 6,670,000 a year ago. Purchases of tangible and intangible assets were EUR 2,797,000 compared to EUR 547,000 a year ago. For the quarter, on the company basis, the company's operating revenues were EUR 9,216,000 compared to EUR 11,531,000 a year ago. LBIT was EUR 13,000 compared to EBIT of EUR 446,000 a year ago. Loss before taxes was EUR 551,000 compared to profit before taxes of EUR 95,000 a year ago. Loss after taxes distributed to shareholders was EUR 569,000 compared to profit after taxes distributed to shareholders of EUR 26,000 a year ago. Basic loss per share was EUR 0.0111 compared to basic earnings per share of EUR 0.0005 a year ago. EBITDA was EUR 676,000 compared to EUR 1,108,000 a year ago. For the six months, on the company basis, the company's operating Revenue was EUR 19,679,000 compared to EUR 24,705,000 a year ago. EBIT was EUR 55,000 compared to EUR 107,000 a year ago. Loss before taxes was EUR 1,014,000 compared to EUR 986,000 a year ago. Loss after taxes distributed to shareholders was EUR 1,040,000 compared to EUR 1,129,000 a year ago. Basic loss per share was EUR 0.0204 compared to EUR 0.0221 a year ago. EBITDA was EUR 1,395,000 compared to EUR 1,433,000 a year ago. Net cash flows from operating activities were EUR 7,540,000 compared to cash out flow of EUR 259,000 a year ago. Purchases of tangible and intangible assets were EUR 2,552,000 compared to EUR 100,000 a year ago.

Lavipharm SA Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2012

Lavipharm SA reported consolidated and company earnings results for the first quarter ended March 31, 2012. For the quarter, on consolidated basis, the company reported operating revenues of EUR 10,005,000 compared to EUR 48,032,000 a year ago. LBIT was EUR 1,042,000 compared to EUR 486,000 a year ago. Loss before taxes was EUR 3,316,000 compared to EUR 3,078,000 a year ago. Loss after taxes distributed to shareholders was EUR 2,644,000 compared to EUR 2,317,000 a year ago. Total loss after taxes distributed to shareholders was EUR 2,069,000 compared to EUR 1,513,000 a year ago. Basic loss per share was EUR 0.0518 compared to EUR 0.0454 a year ago. LBITDA was EUR 164,000 compared to EBITDA of EUR 389,000 a year ago. Adjusted loss per share was EUR 0.0518 compared to EUR 0.0454 a year ago. Net cash flows provided by operating activities was EUR 13,028,000 compared to EUR 3,623,000 a year ago. Purchases of tangible and intangible assets were EUR 2,631,000 compared to EUR 95,000 a year ago. For the quarter, on company basis, the company reported operating revenues of EUR 10,463,000 compared to EUR 13,174,000 a year ago. EBIT was EUR 68,000 compared to LBIT of EUR 339,000 a year ago. Loss before taxes was EUR 463,000 compared to EUR 1,081,000 a year ago. Loss after taxes distributed to shareholders was EUR 471,000 compared to EUR 1,155,000 a year ago. Total loss after taxes distributed to shareholders was EUR 471,000 compared to EUR 1,155,000 a year ago. Basic loss per share was EUR 0.0092 compared to EUR 0.0226 a year ago. EBITDA was EUR 719,000 compared to EUR 325,000 a year ago. Adjusted loss per share was EUR 0.0092 compared to EUR 0.0226 a year ago. Net cash flows provided by operating activities was EUR 5,533,000 compared to EUR 1,633,000 a year ago. Purchases of tangible and intangible assets were EUR 2,548,000 compared to EUR 43,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LAVI:GA €0.14 EUR +0.012

LAVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LAVI.
View Industry Companies
 

Industry Analysis

LAVI

Industry Average

Valuation LAVI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LAVIPHARM S.A., please visit www.lavipharm.gr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.